PONV stands for postoperative nausea and vomiting in adults, which affects roughly 16 million patients annually in the U.S. Enduring surgery is hard enough, and no one should have to deal with nausea and vomiting on top of it. Thankfully, a recent Medscape article discussed a new option to treat PONV. The FDA just approved amisulpride injection, aka Barhemsys from Acacia Pharma, which is the first and only green-lit antiemetic intended to treat PONV. Acacia expects to launch the new injection in the second half of 2020.
Quick Hits: FDA Approves Anti-Nausea Post-Op Injection
16 million Americans suffer from post-op nausea and vomiting each year.
Mar 6, 2020
Recommended
Recommended
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Researched List: Blister Machines for Life Sciences
Need a blister machine for life sciences packaging? Our curated list features companies serving pharmaceutical, medical device, nutraceutical, and cosmetic industries. Download to access company names, locations, machine specifications, descriptions, and more.
Download Now
